ʻO ka mālama ʻana i ka maʻi maʻi maʻi ʻaʻai ʻo Kina 2026: nā lāʻau lapaʻau a me nā kumukūʻai hou - nā halemai kokoke iaʻu 

ʻO ka mālama ʻana i ka maʻi maʻi ʻaʻai i ka makahiki 2026 e pili ana i ka hui pū ʻana o nā kaʻina hana hoʻomaʻamaʻa kiʻekiʻe, nā lāʻau lapaʻau i hoʻopaʻa ʻia, immunotherapy, a me nā ʻenehana intervention i hoʻohālikelike ʻia i ka pae maʻi. ʻO ke kumu kūʻai maʻamau mai $7,000 no ka ʻoki ʻana i ka wā mua a ʻoi aku ma mua o $70,000 no ka mālama piha ʻana o ka pae hope loa e pili ana i nā regimen lāʻau lapaʻau hou. ʻO nā halemai alakaʻi ma Beijing a me Chengdu ke hāʻawi nei i nā koho ʻokiʻoki e like me TACE i hui pū ʻia me ka hoʻomaʻamaʻa target-immune, e loaʻa ana i nā helu hoʻomalu maʻi kiʻekiʻe.

ʻO ka nānā ʻana o ka ʻāina mālama maʻi maʻi ʻaʻai ma 2026

ʻO ka ʻāina o lapaʻau maʻi ʻaʻai ua ulu nui ʻia e ka makahiki 2026, e hoʻololi ana mai nā ala hoʻokahi-modality i nā hoʻolālā hoʻohui maʻalahi. Ua hoʻohui ʻia nā ʻoihana lapaʻau ma Kina, ʻo ia hoʻi ma Beijing a me Chengdu, i ka naʻauao kūlohelohe i loko o nā kahe hana diagnostic a ua hoʻopaʻa i nā kūlana kolepa honua no nā hoʻokolohua lapaʻau.

Ke nānā nei nā holomua hou i ka hoʻonui ʻana i ke ola holoʻokoʻa (OS) a me ke ola holomua ʻole (PFS) ma o ka ʻae ʻana i ka lāʻau lapaʻau. ʻO ka hoʻohui ʻana o ka lāʻau lapaʻau Kina kuʻuna me ka oncology hou i nā kikowaena kikoʻī e hāʻawi i kahi ala holoʻokoʻa, ʻoiai nā halemai kiʻekiʻe e mālama i ka pilina me nā kikowaena olakino honua e like me UPMC e hōʻoia i ke komo ʻana i ka ʻike honua.

Loaʻa i nā poʻe maʻi i kēia lā ka "arsenal" o nā mea kaua therapeutic, me nā lāʻau lapaʻau hou he ʻumikumamāono a me nā ʻenehana holomua ʻehiku i hōʻike ʻia i ka hoʻomaka ʻana o 2026. Ke manaʻo nei kēia mau mea hou e hoʻoponopono i nā carcinoma non-metastatic hepatocellular carcinoma (HCC) a me nā hihia metastatic, e hāʻawi ana i ka manaolana kahi i kaupalena ʻia nā koho mua.

Nā ʻano nui e hoʻokele ana i ka lāʻau lapaʻau hou

ʻO ke ʻano mua ma 2026 ka neʻe ʻana i ka lāʻau lapaʻau pilikino i alakaʻi ʻia e ka genetic profiling a me ka biomarker analysis. Ke hoʻomau nei nā halemai ma ke ʻano he ʻimi noiʻi, ke alakaʻi nei i ka Phase II a me III i nā hoʻokolohua lāʻau lapaʻau e hiki ai i nā poʻe maʻi ke komo koke i nā lāʻau noiʻi hou ma mua o ka ʻae ʻia ʻana o ka mākeke ākea.

ʻO kekahi hoʻololi koʻikoʻi ʻo ia ka hoʻohālikelike ʻana i nā kūkākūkā hui multi-disciplinary (MDT). Ke kauoha nei nā kikowaena maʻi maʻi nui i nā loiloi MDT no kēlā me kēia hihia paʻakikī, e hōʻoia ana i ka hui pū ʻana o nā oncologists oncologists, lāʻau lapaʻau, a me radiation ma kahi hoʻolālā lapaʻau hui. Hoʻemi kēia ala i ka mālama ʻana i nā ʻāpana a hoʻonui i nā hopena.

Ua lilo pū nā mea hana olakino kikohoʻe. Kōkua nā ʻōnaehana diagnostic i kōkua ʻia e AI i ka poʻe radiologists e ʻike i nā ʻeha o ka wā mua me ka ʻoi aku ka pololei, ʻoiai nā kikowaena noiʻi lapaʻau kikohoʻe e nānā i nā ʻikepili nui e wānana i nā pane o nā mea maʻi i nā hui immunotherapy kūikawā.

ʻO nā lāʻau lapaʻau Breakthrough a me nā ʻae hou i 2026

ʻO ka makahiki 2026 ka manawa koʻikoʻi no nā hana lāʻau lapaʻau i ka maʻi maʻi ʻaʻai, me nā mea nui e loaʻa ana i ka ʻae kānāwai a i ʻole ke hōʻea ʻana i nā milestone hoʻokolokolo koʻikoʻi. Kuhi ʻia kēia mau lāʻau lapaʻau i nā ala molekala kūikawā e pale ai i ka ulu ʻana o ka maʻi maʻi a hoʻonui i ka hiki o ka ʻōnaehana pale e hakakā i nā cell cancer.

Ua hoʻolalelale nā kino hoʻoponopono ma Kina a me ʻAmelika Hui Pū ʻIa i ke kaʻina loiloi no ka hoʻohiki ʻana i nā lāʻau lapaʻau hui. Ua neʻe nui ka manaʻo i nā lāʻau lapaʻau mua e hoʻohui i nā tyrosine kinase inhibitors (TKIs) me nā mea hoʻopaʻapaʻa pale pale, e hōʻike ana i ka ʻoi aku ka maikaʻi ma mua o nā monotherapies kahiko.

ʻO Lenvatinib a me nā lāʻau lapaʻau hui

ʻO Lenvatinib, i ʻike ʻia ma ke ʻano kālepa ʻo Lenvima, he pōhaku kihi i ka mālama ʻana i ka HCC unresectable. I Iulai 2025, ua loaʻa iā ia kahi ʻae hōʻailona hou i Kina no ka hoʻohana pū ʻana me ka pembrolizumab a me Transarterial Chemoembolization (TACE).

ʻO kēia "TACE + Target-Immune" regimen e hōʻike ana i ka hana mua i ʻae ʻia i ka honua e hui pū ana i kēia mau ʻano ʻekolu. Ua hōʻike ʻia ka ʻikepili lapaʻau mai ka haʻawina Phase III LEAP-012 i ka helu ola holoʻokoʻa he 24 mau mahina o 75% no ka hui hui, ʻoi aku ma mua o ka 69% i ʻike ʻia ma nā pūʻulu mana.

ʻO ka median progression-free survival (PFS) no nā poʻe maʻi ma kēia triple therapy a hiki i 14.6 mahina, kahi hoʻomaikaʻi nui ma luna o nā mahina 10.0 i ʻike ʻia me ka mālama maʻamau. Hoʻopaʻa kēia ʻae i ka hoʻolālā o ka hoʻouka ʻana i ka maʻi maʻi ma o nā mīkini he nui i ka manawa like: kaohi ʻana i ka hāʻawi koko, kaohi ʻana i nā hōʻailona ulu, a me ka hoʻoulu ʻana i ka pane immune.

Finotonlimab a me nā Hana Hou

Ua holomua ka ʻāpana lāʻau lapaʻau kūloko o Kina me ka ʻae ʻana o Finotonlimab (SCT-I10A), kahi antibody anti-PD-1 IgG4 monoclonal recombinant i hoʻomohala ʻia e Sinocelltech. Ua ʻae ʻia i ka hoʻomaka ʻana o 2025 no HCC, hoʻohana pinepine ʻia i ka hui pū me nā biosimilars bevacizumab.

Ua hōʻike ʻia nā hoʻokolohua lapaʻau i kahi helu pane pane (ORR) o 33% no ka hui pū ʻana, ʻoi aku ka kiʻekiʻe ma mua o ka 4% i nā hui hoʻohālikelike. Ua ʻike nā poʻe maʻi i ka PFS median o 7.1 mau mahina a me kahi OS median o 22.1 mau mahina, e hōʻike ana i kahi hōʻemi o 40% i ka hopena o ka make i hoʻohālikelike ʻia i nā mana.

Hāʻawi kēia lāʻau lapaʻau i kahi koho kūpono no nā poʻe maʻi i loko o Kina, e hāʻawi ana i ka lāʻau lapaʻau kiʻekiʻe me ka ʻole o ke kumu kūʻai kumukūʻai pili pinepine me nā mea ola i lawe ʻia mai. Hōʻike ka holomua i ka ulu ʻana o nā ʻoihana biotech kūloko e hoʻokūkū ma ke kahua honua.

ʻO Camrelizumab a me ka ʻike honua

Ma kahi hoʻomohala nui no ka ʻike honua, ua ʻae ʻia ka camrelizumab ʻo Hengrui Medicine i hui pū ʻia me apatinib mai ka US FDA no ka loiloi i ka hoʻomaka ʻana o 2026. Kuhi ʻia kēia noi i ka lāʻau lapaʻau mua no ka HCC unresectable a metastatic paha.

Ua hōʻike ka regimen i kahi OS median o 22.1 mahina a me kahi PFS median o 5.6 mau mahina i nā hoʻokolohua honua e pili ana i nā poʻe 543 ma waena o 13 mau ʻāina. Hoʻonohonoho ʻia ka lā hoʻoholo hoʻoholo a ka FDA no Iulai 2026, hiki ke hana i kēia koho maʻamau o ka mālama honua.

ʻO ka nui o ka hoʻopukapuka ʻana i ka noiʻi, ʻoi aku ka nui o 3.2 biliona RMB, e hōʻike ana i ka hoʻokō ʻana i ka hoʻomohala ʻana i nā pūʻolo data ikaika e hoʻokō i nā kūlana hoʻoponopono honua. Hiki i kēia ʻae ʻia ke hoʻololi hou i ka mākeke honua no ka immunotherapy maʻi kanesa.

ʻIke ʻana i ke kumukūʻai o ka mālama ʻana i ka maʻi maʻi ate ma 2026

Hoʻomaopopo i ka hopena kālā o lapaʻau maʻi ʻaʻai he mea koʻikoʻi no nā maʻi a me nā ʻohana hoʻolālā mālama. He ʻokoʻa nā kumukūʻai ma muli o ke kahua o ka maʻi ʻana, ke ʻano o ka lāʻau lapaʻau i koho ʻia, kahi ʻāina, a inā hoʻohana ʻia nā lāʻau lapaʻau i lawe ʻia mai a i ʻole.

I ka makahiki 2026, hiki ke hoʻolilo ʻia ka huina kālā mai kahi $7,000 no nā hana ʻokiʻoki mua a i ʻoi aku ma luna o $70,000 no ka hoʻokele holomua holomua e pili ana i ka transplantation a i ʻole immunotherapy lōʻihi. He kuleana koʻikoʻi ka hoʻopiʻi ʻinikua a me nā kōkua aupuni i ka hoʻēmi ʻana i kēia mau lilo.

Na koina ma ke ano ma'i

ʻO ka maʻi maʻi ʻaʻai mua, ka mea maʻamau i mālama ʻia me ka hōʻoki ʻoki ʻana a i ʻole ka radiofrequency ablation, maʻamau e loaʻa nā kumukūʻai ma waena o $7,000 a me $21,000. Hoʻopili kēia i nā diagnostics pre-operative, ke kaʻina hana ʻoki ponoʻī, anesthesia, a me nā uku hale maʻi.

No ka maʻi waena, kahi i hui pū ʻia me ka lāʻau lapaʻau i manaʻo ʻia, hāʻule maʻamau nā lilo ma waena o $14,000 a me $28,000. ʻO ke kumukūʻai mau o nā TKI waha e like me lenvatinib a i ʻole sorafenib ka mea nui i kēia huina, ʻoiai e lawe mau ʻia kēia mau lāʻau lapaʻau.

Pono ka maʻi maʻi hope a i ʻole metastatic i ka mālama piha ʻana, me ka chemotherapy, immunotherapy, a me nā kaʻina hana hana hou. Hiki ke piʻi nā kumukūʻai ma ʻaneʻi i $21,000–$42,000 a ʻoi aku paha. Inā manaʻo ʻia he pono ka hoʻololi ʻana i ke akepaʻa, hiki ke piʻi i ka $35,000 a i ka $70,000 ka nui o ka bila, me ka hoʻohālikelike ʻana i nā mea hāʻawi a me nā lāʻau anti-rejection ola holoʻokoʻa.

Nā lilo o kēlā me kēia mahina no ka lāʻau lapaʻau i manaʻo ʻia

ʻO ka lāʻau lapaʻau i hoʻopaʻa ʻia he ʻāpana nui o nā kumukūʻai mālama mau. Hiki ke kūʻai ʻia nā lāʻau lapaʻau e like me sorafenib a i ʻole lenvatinib ma waena o $2,800 a me $4,200 i kēlā me kēia mahina ma nā kūlanakauhale papa hoʻokahi. Ma nā kūlanakauhale papa ʻelua, emi iki paha nā kumukūʻai ma muli o nā kulekele kumu kūʻai āpana.

Hāʻawi nā mea ʻokoʻa ʻē aʻe e like me apatinib i kahi koho kūpono loa, me nā kumukūʻai o kēlā me kēia mahina mai $700 a i $1,400. Ke hui pū ʻia me nā mea olaola e like me bevacizumab, pono e manaʻo ʻia nā lilo o kēlā me kēia mahina o $700 a i $1,100.

ʻO ka nānā mau ʻana kekahi kumu. ʻO nā kiʻi kiʻi a me nā ho'āʻo hana ate, koi ʻia i kēlā me kēia pule e loiloi i ka pane ʻana i ka lāʻau lapaʻau, e hoʻohui ma kahi o $110 a i $210 i kēlā me kēia kipa. Ma luna o hoʻokahi makahiki, e hōʻiliʻili kēia mau koina ancillary, pono e hoʻolālā pono i ke kālā.

Uku Uku a me Radiotherapy

ʻO nā kaʻina hana interventional e like me Transarterial Chemoembolization (TACE) he mea maʻamau no ka mālama ʻana i ka ulu ʻana o ka maʻi maʻi kūloko. Hoʻokahi manawa maʻamau ma waena o $2,800 a me $7,000. ʻO ka hapa nui o nā maʻi e koi i nā kau he nui, pinepine ʻekolu a ʻelima, hoʻolaha i kekahi mau mahina.

ʻO ke kumukūʻai o ka lāʻau lapaʻau e pili ana i ka ʻenehana i hoʻohana ʻia. He $1,400 a i $4,200 paha ke kumukūʻai o nā papa radiotherapy maʻamau. Eia nō naʻe, ʻoi aku ka maikaʻi o nā ʻenehana kikoʻī e like me ka proton beam therapy, ka mea e mālama pono ai i ke kino olakino, hiki ke ʻoi aku ma mua o $ 14,000 i kēlā me kēia papa.

ʻO nā lāʻau lapaʻau ablative kūloko e like me ka microwave a i ʻole radiofrequency ablation ʻoi aku ka liʻiliʻi o ke kumukūʻai, mai $2,800 a i $5,600 no ke kaʻina hana. Hoʻohana pinepine ʻia kēia no nā maʻi maʻi liʻiliʻi a i ʻole nā ​​​​moho no ka ʻoki nui.

ʻO nā halemai kiʻekiʻe no ka mālama ʻana i ka maʻi maʻi ate ma Kina

ʻO ke koho ʻana i ke keʻena olakino kūpono ka mea nui no nā hopena kūleʻa. Ua hoʻokiʻekiʻe ʻo Kina i kekahi mau halemai o ka honua i hoʻolalelale i nā maʻi hepatobiliary, i lako me nā ʻenehana hou a me nā hui loea kaulana. Ua puka mai ʻo Beijing a me Chengdu ma ke ʻano he alakaʻi nui no ka mālama ʻana i ka maʻi maʻi ate ma 2026.

ʻAʻole kēia mau keʻena he mau lawelawe lapaʻau wale nō akā he poʻe komo pū kekahi i nā ʻoihana noiʻi honua. Nui ka poʻe e paʻa i ka ʻae ʻana ma ke ʻano he mau keʻena hoʻokolohua lāʻau lapaʻau (GCP) a hui pū me nā hoa pili honua e lawe i nā lāʻau lapaʻau hou loa i nā maʻi.

ʻO nā hui alakaʻi ma Beijing

Hoʻokipa ʻo Beijing i nā keʻena kiʻekiʻe i hoʻolaʻa ʻia no ka oncology. Hāʻawi like nā halemai maʻi tumora kūikawā a me nā halemai kula kiʻekiʻe Grade-A i nā lawelawe maʻi maʻi ate. Hoʻonohonoho pinepine ʻia kēia mau kikowaena ma ke ʻano he mau ʻāpana kuikahi hōʻike maʻi maʻi mua a me nā hub kūkākūkā MDT.

Hoʻokahi keʻena koʻikoʻi i kahi keʻena i alakaʻi ʻia e nā poʻe loea me ka ʻoi aku o 30 mau makahiki o ka ʻike ma ke ʻano hepatobiliary. Hoʻolaha ko lākou hui i nā ʻokiʻoki paʻakikī, ka hoʻokele ʻana i ka ʻawaʻawa bile kiʻekiʻe, a me ka hoʻololi ʻana i ka ate no ka maʻi hope. Ua loaʻa iā lākou nā makana holomua ʻepekema a me ka ʻenehana.

ʻO ka hui pū ʻana me nā hui honua e like me ke Kulanui o Pittsburgh Medical Center (UPMC) e hoʻonui i ko lākou hiki. Hoʻomaʻamaʻa ia mau hui i ka hoʻololi ʻana i nā ʻano hana hoʻomaʻamaʻa a me ke komo ʻana i nā hoʻokolohua lapaʻau honua, e hōʻoia ana i nā mea maʻi e loaʻa ka mālama e kūlike me nā hana maikaʻi loa o ka honua.

Eia kekahi, ua hoʻokumu kēia mau haukapila i nā kikowaena noiʻi olakino. Ma ka hoʻohana ʻana iā AI no ka maʻi maʻi kōkua a me ka hoʻolālā ʻana i ka mālama ʻana, hoʻomaikaʻi lākou i ka pololei diagnostic a pilikino i nā hoʻolālā therapeutic, e hoʻonohonoho ana i kahi pae no ka mālama olakino akamai i ka oncology.

Nā Hale Kūlana Nui ma Chengdu

ʻO Chengdu kekahi kikowaena koʻikoʻi no ka mālama ʻana i ka maʻi maʻi ate ma ke komohana Kina. Ke kū nei ʻo West China Hospital o ke Kulanui ʻo Sichuan ma ke ʻano he halemai kula kiʻekiʻe Grade-A me ka ʻike hohonu i nā maʻi ate. ʻO kāna mau mea hana kiʻekiʻe a me ka ikaika ʻenehana ikaika e lilo ia i wahi makemake no nā hihia paʻakikī.

ʻO ka Halemai maʻi maʻi ʻo Sichuan, kahi keʻena oncology tertiary kūikawā, e kālele wale ana i ka maʻi maʻi a me ka mālama ʻana. Loaʻa iā ia nā lako radiotherapy kiʻekiʻe a me kahi hui kahu hānai ʻoihana i hoʻolaʻa ʻia no ka hoʻokele ʻana i nā hopena ʻaoʻao o nā lāʻau lapaʻau maʻi maʻi.

Hāʻawi ka Halemai Kanaka ʻEkolu o Chengdu i nā ikaika kūʻokoʻa i kāna ʻOihana Hepatology a me Gastroenterology. ʻIke ʻia no kāna ʻano ʻokoʻa i ka maʻi a me ka mālama ʻana, hāʻawi ia i ka mālama hoʻohui ʻia no nā ʻano hepatobiliary like ʻole, me nā maʻi malignancies.

Hoʻohui ʻia, kaulana ka Halemai Nui o Chengdu Military Command no kāna keʻena ʻoihana hepatobiliary, kahi loea lapaʻau koʻikoʻi ma ke komohana hema o Kina. ʻOi maikaʻi ia i nā ʻoki ʻokiʻoki paʻakikī a me nā lāʻau interventional invasive liʻiliʻi, e mālama ana i kahi pae ʻenehana alakaʻi ma ka ʻāina.

No nā poʻe maʻi makemake i ka lāʻau lapaʻau integrative, hui pū ka Halemai Hoʻohui o Chengdu University of Traditional Chinese Medicine i nā lāʻau lapaʻau kuʻuna me nā hana lapaʻau hou. Kākoʻo kēia ʻano holistic i ka hoʻōla ʻana o ka maʻi a mālama i nā hōʻailona me ka mālama maʻamau.

Hoʻohālikelike Hoʻohālikelike o nā ʻano Lapaʻau

ʻO ke koho ʻana i ke ala lapaʻau kūpono e pili ana i nā ʻano like ʻole me ka nui o ka tumo, ka wahi, ka hana o ka ate, a me ke kūlana hana maʻi. Aia ma lalo kahi hoʻohālikelike o nā ʻano hana lapaʻau mua i loaʻa i ka makahiki 2026 e kōkua i ka hoʻomaopopo ʻana i kā lākou kuleana kūʻokoʻa.

ʻO nā pono a me nā pōʻino o nā ala nui

ʻO kēlā me kēia koho lapaʻau e lawe i nā pono kūikawā a me nā palena. ʻO ka hoʻomaopopo ʻana i kēia mau mea kōkua i ka hoʻonohonoho ʻana i nā manaʻolana maoli a me ka hoʻoholo ʻana i ka ʻike ma ke kūkākūkā ʻana me nā limahana lapaʻau.

• ʻO ka ʻoki ʻoki ʻana: Hāʻawi i ka manawa kiʻekiʻe loa o ka hoʻōla no nā maʻi kūpono. Eia nō naʻe, he invasive, koi i ka manawa hoʻihoʻi nui, a hiki wale ke hana inā lawa ka hana o ke ake.
• ʻO ka hoʻololi ʻana i ke akepaʻa: Hoʻoponopono maikaʻi i ka maʻi kanesa a me ka maʻi o ke ake. ʻO nā hemahema koʻikoʻi ka liʻiliʻi o nā mea hāʻawi, ke kumu kūʻai kiʻekiʻe, a me ka pono o ka immunosuppression ola.
• Kuhi ʻia a me ka Immunotherapy: Hāʻawi i ka mana ʻōnaehana no ka maʻi holomua a ua hōʻike i nā pōmaikaʻi ola maikaʻi i nā hoʻokolohua hou. Hiki i nā hopena ʻaoʻao ke komo i ka hypertension, ka maʻi lima-wāwae, a me nā hanana ʻino e pili ana i ka immune e pono ai ka hoʻokele.
• TACE: Maikaʻi no ka hoʻomalu ʻana i ke kaumaha o ka maʻi maʻi i loko o ke ake me ka ʻole o ka ʻona. Pono pinepine ia i nā kau hou a ʻaʻole kūpono paha i nā poʻe maʻi me ka hana ʻino o ka ate a i ʻole ka maʻi extrahepatic nui.

Alakaʻi ʻanuʻu i ka Navigation Treatment

ʻO ka hoʻokele ʻana i ka huakaʻi paʻakikī o ka mālama ʻana i ka maʻi maʻi ate he mea paʻakikī. ʻO kahi ala i kūkulu ʻia e hōʻoia i ka loaʻa ʻana o nā maʻi i ka manawa kūpono a me ka mālama kūpono. Hōʻike nā ʻanuʻu ma lalo i ke ala maʻamau mai ka kānalua a hiki i ka hoʻomaka ʻana o ka mālama ʻana.

• KaʻAnuʻu 1: ʻIke mua a me ka ʻike: E hoʻomaka me ka nānā maʻamau inā loaʻa iā ʻoe nā mea pilikia e like me ka hepatitis B/C a i ʻole cirrhosis. E hoʻohana i nā hōʻike koko ultrasound a me AFP. Inā loaʻa nā mea ʻino, e hoʻomau i ka CT a i ʻole MRI i hoʻohālikelike ʻia no ka ʻike kikoʻī.
• KaʻAnuʻu 2: Loiloi Hoʻonaʻauao Multidisciplinary: Ke ʻike ʻia, e ʻimi i kahi kūkākūkā MDT ma kahi kikowaena kūikawā. E loiloi pū nā ʻoka, nā oncologists, a me nā radioologists i kāu hihia e hoʻoholo ai i ke kahua a paipai i ka hoʻolālā lapaʻau maikaʻi loa.
• KaʻAnuʻu Hana 3: Genetic and Biomarker Testing: I ka makahiki 2026, ʻoi aku ka maʻamau o ka profiling molecular. ʻO ka hoʻāʻo ʻana no nā biomarkers kikoʻī hiki ke alakaʻi i ke koho ʻana i nā lāʻau lapaʻau i manaʻo ʻia a wānana i ka pane ʻana i ka immunotherapy, pilikino i ka hoʻolālā lapaʻau.
• KaʻAnuʻu 4: Hoʻomaka Lapaʻau: E hoʻomaka koke i ka lāʻau lapaʻau i ʻaelike ʻia. Inā he ʻoki paha, lāʻau lapaʻau, a i ʻole radiology interventional, ʻo ka mālama ʻana i ka papa kuhikuhi he mea koʻikoʻi no ka hoʻonui ʻana i ka pono.
• KaʻAnuʻu 5: Ka nānā ʻana a me ka hahai ʻana: Pono nā mākaʻikaʻi maʻamau e nānā i ka pane ʻana o ka lāʻau a mālama i nā hopena ʻaoʻao. Hana ʻia nā hoʻāʻo kiʻi a me ke koko i kēlā me kēia 2-3 mahina e hoʻoponopono i ka hoʻolālā e like me ka mea e pono ai.

Koʻikoʻi o nā hoʻokolohua lapaʻau

Hāʻawi ke komo ʻana i nā hoʻokolohua lapaʻau i ke komo ʻana i nā lāʻau lapaʻau ʻokiʻoki ma mua o ka loaʻa ʻana o ka nui. Nui nā halemai kiʻekiʻe ma Beijing a me Chengdu i hōʻoia ʻia e GCP, e hana ana i nā hoʻokolohua Phase II a me III no nā lāʻau lapaʻau hou.

Loaʻa i nā poʻe maʻi i hoʻopaʻa inoa ʻia i kēia mau hoʻāʻo i ka nānā pono ʻana a me ka mālama piha ʻana me ka uku ʻole no ka lāʻau hoʻokolokolo. Ma ke kūkākūkā ʻana i ka pono o ka hoʻokolokolo me kāu kauka hiki ke wehe i nā puka i nā lāʻau lapaʻau hou e like me nā mea hoʻopaneʻe PD-1 hou loa a i ʻole nā ​​papa hoʻohui hou.

Eia kekahi, ʻo ka hāʻawi ʻana i ka noiʻi lapaʻau e kōkua i ka holomua o ke kula, e pōmaikaʻi ana i nā poʻe maʻi e hiki mai ana. ʻO ka ʻikepili i hana ʻia mai kēia mau haʻawina i kumu no nā alakaʻi hou a me nā ʻae ʻia, e alakaʻi ana i ka ulu ʻana o ka mālama maʻi maʻi ate.

Nā noi honua maoli a me nā hiʻohiʻona maʻi

Loaʻa ka waiwai o ka ʻike manaʻo ke hoʻohana ʻia i nā hiʻohiʻona maoli. ʻO ka nānā ʻana i nā moʻolelo maʻi maʻamau e hōʻike ana i ke koho ʻana i nā ala lapaʻau like ʻole e pili ana i nā kūlana o kēlā me kēia kanaka i ka ʻāina olakino 2026.

E noʻonoʻo i kahi maʻi i ʻike ʻia me ka HCC pae mua i ʻike ʻia i ka wā o ka nānā maʻamau. Me ka puʻupuʻu liʻiliʻi hoʻokahi a mālama ʻia ka hana o ka ate, hiki iā lākou ke hana ʻoki ʻoki. Ma hope o ka ʻoki ʻana, hiki iā lākou ke kuhikuhi ʻia i ka adjuvant targeted therapy no ka pale ʻana i ka hoʻi hou ʻana, ma muli o nā kuʻina hōʻike hou loa.

I kekahi hiʻohiʻona ʻē aʻe, loaʻa ka maʻi i ka maʻi waena waena e hōʻike ana i nā nodule he nui akā ʻaʻohe pālahalaha mamao. ʻO ka TACE i hui pū ʻia me ka immunotherapy ke ala i ʻōlelo ʻia. Ke manaʻo nei kēia hoʻolālā ʻelua e hōʻemi i nā ʻōpū ma ka ʻāina aʻo ka hoʻoulu ʻana i kahi pane ʻōnaehana systemic e hopu i nā micrometastases.

No nā hihia kiʻekiʻe kahi i koho ʻole ʻia ai ke ʻoki, hoʻololi ka manaʻo i ka hoʻolōʻihi ʻana i ke ola a mālama i ka maikaʻi o ke ola. ʻO ke ʻano o ka TKI waha a me ka immunotherapy IV, hiki ke hoʻokomo i nā mea hana hou i ʻae ʻia e like me finotonlimab, lilo i mea maʻamau. Hoʻohui mua ʻia ke kākoʻo mālama palliative e mālama i nā hōʻailona a hāʻawi i ke kākoʻo noʻonoʻo.

Hoʻohui i nā lāʻau lapaʻau kuʻuna a me nā lāʻau hou

Ma kekahi mau wahi e like me Chengdu, ʻo ka hoʻohui ʻana o Traditional Chinese Medicine (TCM) me ka oncology maʻamau he hiʻohiʻona kūʻokoʻa. Hāʻawi nā halemai i hui pū ʻia me nā kula ʻo TCM i nā lāʻau lapaʻau hui kahi e kākoʻo ai nā mea kanu lāʻau i ka hana o ka ate a hōʻemi i ka ʻona i hoʻokomo ʻia i ka chemotherapy.

ʻAʻole hoʻololi kēia ʻano hoʻohui i ka mālama maʻamau akā hoʻopiha iā ia. Hōʻike ka poʻe maʻi i ka hoʻomaikaʻi ʻana i ka ʻai, ʻoi aku ka maikaʻi o ka hiamoe, a me ka hoʻonui ʻana i ka hoʻomanawanui i nā lāʻau koʻikoʻi. ʻO ia holistic holistic e kamaʻilio i ke kanaka holoʻokoʻa, e kūlike me ka ulu nui o ka mālama ʻana i ka mālama maʻi.

Eia nō naʻe, he mea koʻikoʻi ke kūkākūkā ʻia nā mea hoʻohui lāʻau me ka hui oncology e pale aku i nā pilina lāʻau. ʻO ke alakaʻi ʻoihana e hōʻoia i ka palekana a me ka synergistic ka hui ʻana ma mua o ka pōʻino.

ʻO ka Outlook e hiki mai ana a me nā ʻenehana hou

Ke nānā nei ma mua o 2026, ʻike ʻia ka wā e hiki mai ana o ka mālama ʻana i ka maʻi kanesa me ka hoʻomau hou ʻana. Ke hele nei ka noiʻi ʻana i nā mīkini huli ʻoi aku ka pololei a me nā immunotherapies e hiki mai ana e hōʻemi i ke kūʻē.

Manaʻo ʻia ʻo Artificial Intelligence e pāʻani i kahi hana ʻoi aku ka nui, ʻaʻole wale i ka maʻi maʻi akā i ka wānana ʻana i nā hopena lapaʻau a me ka hoʻonui ʻana i nā papa kuhikuhi dosing. Hiki i nā māhoe kikohoʻe o nā ake maʻi ke hoʻohālikelike i ka pane ʻana o ka maʻi koko i nā lāʻau lapaʻau ma mua o ka lawelawe ʻana.

Ke hoʻokolokolo ʻia nei nā ʻenehana hoʻoponopono Gene a me CAR-T cell therapy no nā maʻi maʻi paʻa e like me HCC. ʻOiai i ka wā mua, paʻa kēia mau ʻano i ka hiki ke hāʻawi i nā koho curative no nā poʻe maʻi i kēia manawa ka manaʻolana.

ʻO ka hui pū ʻana ma waena o nā hui Kina a me nā hoa pili honua e hōʻoia i ka hiki koke ʻana o kēia mau holomua. Ke hoʻonui nei ka "mea kaua" e kūʻē i ka maʻi maʻi ate, hoʻololi ka pahuhopu mai ka hoʻolōʻihi ʻana i ke ola i ka loaʻa ʻana o ke kala lōʻihi a me ka hoʻōla hana.

Manaʻo no nā koho lapaʻau maʻi maʻi ate

Hōʻike ka makahiki 2026 i kahi manawa hoʻololi i lapaʻau maʻi ʻaʻai, i hōʻike ʻia e nā ʻano lāʻau lapaʻau maikaʻi, nā ʻenehana ʻokiʻoki kiʻekiʻe, a me nā hoʻolālā mālama pilikino. Mai ka ʻae ʻana i nā regimen hui ikaika e like me Lenvatinib me ka pembrolizumab a hiki i ka ʻike honua ʻana i nā hana hou o ka home e like me camrelizumab, ʻoi aku ka nui o nā koho ma mua o ka wā ma mua.

ʻOiai hiki ke koʻikoʻi nā kumukūʻai, mai nā tausani a i ʻumi kaukani kālā ma muli o ka paʻakikī o ka mālama ʻana, ʻo ka loaʻa ʻana o ka ʻinikua, nā generics home, a me nā hoʻokolohua lapaʻau e kōkua i ka hoʻēmi ʻana i nā kaumaha kālā. ʻO ke koho ʻana i kahi haukapila kaulana me kahi hui multidisciplinary ʻo ia ka hana koʻikoʻi loa i ka hoʻokele ʻana i kēia huakaʻi.

Me ka hoʻomau ʻana i ka noiʻi a me ka launa pū ʻana o ka honua, ke hoʻomau nei ka prognosis no nā maʻi maʻi maʻi ate. ʻO ka ʻike mua ʻana, i hui pū ʻia me nā holomua therapeutic hou, hāʻawi i kahi ala maoli i ke ola lōʻihi a me ka maikaʻi o ke ola no ka poʻe i loaʻa i kēia maʻi paʻakikī.